Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est

Benzinga Newsdesk www.benzinga.com Positive 75.1%

Neg 0% Neu 0% Pos 75.1%

Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $21.000 million-$22.600 million vs $21.850 million analyst estimate.

Comments

No comments yet. Be the first!